Efficacy of Tocilizumab in Patients with COVID-19
Background and purpose: Tocilizumab (TCZ), a monoclonal antibody against interleukin-6 (IL-6) receptor, is emerged as an alternative treatment for COVID-19 patients with a risk of cytokine storms. This study aimed at investigating the efficacy of TCZ in patients with COVID-19. Materials and methods:...
Main Authors: | Ahmad Alikhani, Zahra Nekoukar, Minoo Moghimi, Maysam Rezapour, Seyyed Javad Boskabadi, Amir Mohammad Shabani, Hamideh Abbaspour Kasgari |
---|---|
Format: | Article |
Language: | English |
Published: |
Mazandaran University of Medical Sciences
2022-12-01
|
Series: | Journal of Mazandaran University of Medical Sciences |
Subjects: | |
Online Access: | http://jmums.mazums.ac.ir/article-1-18510-en.html |
Similar Items
-
Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19
by: Shoji Hashimoto, et al.
Published: (2021-09-01) -
Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
by: Corrado Pelaia, et al.
Published: (2021-03-01) -
Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia
by: Daria Fomina, et al.
Published: (2020-10-01) -
Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection
by: Al Shaimaa Ibrahim Rabie, et al.
Published: (2023-02-01) -
Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies
by: Monica A. Kaminski, et al.
Published: (2020-12-01)